摘要
背景与目的:Ⅰ～Ⅲa期非小细胞肺癌(non-small cell lung cancer,NSCLC)根治术后5年生存率不足40%,术后复发的治疗迫待解决。本研究旨在观察NSCLC术后复发患者接受培美曲塞治疗的近期疗效与不良反应。方法:分析2006年1月—2008年9月间40例接受培美曲塞(商品名:力比泰)单药或联合卡铂治疗的NSCLC术后复发患者的疗效与不良反应。结果:40例患者中无CR,PR10例(25.00%),SD19例(47.50%),PD11例(27.50%)。疾病缓解率(CR+PR)为25.00%;疾病控制率(CR+PR+SD)为72.50%。Fisher精确检验提示,疾病缓解率方面,不同性别、NSCLC病理类型、培美曲塞单药或联合卡铂化疗之间不存在显著性差异。但在疾病控制率方面,女性优于男性(91.30%:47.06%,P=0.034),腺癌患者优于非腺癌患者(87.10%:22.22%,P=0.001),力比泰单药与联合化疗相比无显著性差异。所有患者中位生存期10.70个月,无进展生存期5.18个月,腺癌患者无进展生存期优于非腺癌患者。结论:培美曲塞治疗术后复发性NSCLC安全有效。
Background and purpose：Five-year survival rate of post-operation patients with non-small cell lung cancer （NSCLC） is less than 40%.Treatments after recurrence are difficult.Our study aimed to evaluate the efficacy of pemetrexed on postoperative recurrence of NSCLC.Methods：From Jan.2006 to Sep.2008,40 NSCLC with postoperative recurrence were observed.All patients had received pemetrexed （ALIMTA） 500 mg/m 2 or carboplatin conbined.Results：Among the 40 patients,partial response in 10 patients （25.00%）,stable disease in 19 patients （47.50%）,progressive disease in 11 patients （27.50%）.The total response rate was 25.00% and clinical benefit control rate was 72.50%.Pemetrexed had significantly better disease control rate in female than in male （91.30% vs 47.06%,P=0.034）,in adenocarcinoma patients than in non-adenocarcinoma＇s （87.10% vs 22.22%,P=0.001）.Median overall survival time （MST） was 10.70 months.Progression-free survival time （PFS） was 5.18 months.Adenocarcinoma patients had longer PFS than non-adenocarcinoma patients.Conclusion：Pemetrexed demonstrates significant antitumor activity and good tolerance in these patients.
出处
《中国癌症杂志》
CAS
CSCD
北大核心
2010年第3期218-221,共4页
China Oncology
关键词
非小细胞肺癌
培美曲塞
手术
non-small cell lung cancer
pemetrexed
operation
